A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Stopped early · Phase 2

Conditions studied: Leukemia, Leukemia, Lymphocytic, Chronic

In brief

The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding to treatment.

Key facts

Study ID

NCT00076401

Run by

Pharmacyclics LLC.

People needed

27

Last updated by the study team

2014-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years old
• Refractory or relapsed CLL
• ECOG performance status score of 0, 1, or 2
• Each patient must sign a study-specific informed consent form

You may not qualify if…

• Laboratory values of:
• Platelet count <30,000/uL
• AST or ALT >2 x the upper limit of normal (ULN)
• Total bilirubin >2 x ULN
• Creatinine >2.0 mg/dL
• Chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic biologic anticancer therapy within 21 days before beginning study treatment
• Women who are pregnant or lactating

Where it is running

• Ohio State University Medical Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.